Patents by Inventor Jorg Kaufmann

Jorg Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240408014
    Abstract: The present invention is related to a preparation for use in therapy, wherein therapy comprises local administration of the preparation to a subject, wherein the local administration is selected from the group consisting of intramuscular administration, subcutaneous administration, intravitreal administration, intrathecal administration, intratumoral administration, intracerebral administration and intradermal administration, wherein the preparation comprises lipid nanoparticles, wherein the lipid nanoparticles comprise a lipid composition comprising a first and a second lipid, and a therapeutically active nucleic acid molecule, and, wherein the lipid nanoparticles are amphoteric, overall neutrally charged lipid nanoparticles.
    Type: Application
    Filed: August 13, 2024
    Publication date: December 12, 2024
    Inventors: Volker FEHRING, Oliver KEIL, Jörg KAUFMANN, Akanksha MOGA
  • Publication number: 20230263819
    Abstract: The present invention is related to a composition comprising a lipid composition, a tricarboxylic acid and a nucleic acid molecule, wherein the lipid composition comprises a cationic lipid, a neutral lipid and a shielding lipid, wherein a positive charge excess arising from a larger number of positive charges provided by the cationic lipid molecules in the composition compared to the smaller number of negative charges provided by the nucleic acid molecules in the composition is compensated by the charges provided by the tricarboxylic acid; and methods of use of such composition.
    Type: Application
    Filed: August 10, 2022
    Publication date: August 24, 2023
    Inventors: Volker FEHRING, Jörg KAUFMANN, Oliver KEIL, Daniel TONDERA
  • Patent number: 11715309
    Abstract: A method for producing security elements in an image which are not visible to the human eye and which cannot be copied, in particular for checking the authenticity of images. The image is imaged by means of a halftone, the halftone consisting of individual image dots arranged adjacent to each other. This is characterized in that at least one field having a random geometric shape or freeform is defined in the image/the halftone. By means of manipulation of image dots in the field and/or by means of manipulation of the entire field, an encrypted information that cannot be copied is stored for comparison with at least one database and the serial number is displayed by means of contours formed in the halftone.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: August 1, 2023
    Assignee: authentic.network GmbH
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Patent number: 11587339
    Abstract: A method for checking the authenticity of products, by checking an image (A) of a product. The proof of authenticity is not visible to the human eye and cannot be copied. This is characterized in that a code stored in a halftone image by manipulation of dots and/or a manipulated field bounded in the halftone image can be read by means of an optical device and compared with a retrievable value in at least one database. In at least one field (F1 to F5) a part of a serial number is determined which describes the structure of the serial number and a hash function used for transmitting the serial number to the database, and this is also characterized in that the serial number is subsequently assembled and encrypted with the corresponding hash function.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: February 21, 2023
    Assignee: Industry 365 UG (Haftungsbeschränkt)
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Patent number: 11578328
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: February 14, 2023
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20210261980
    Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 26, 2021
    Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
  • Publication number: 20210248369
    Abstract: A method for checking the authenticity of products, by checking an image (A) of a product. The proof of authenticity is not visible to the human eye and cannot be copied. This is characterized in that a code stored in a halftone image by manipulation of dots and/or a manipulated field bounded in the halftone image can be read by means of an optical device and compared with a retrievable value in at least one database. In at least one field (F1 to F5) a part of a serial number is determined which describes the structure of the serial number and a hash function used for transmitting the serial number to the database, and this is also characterized in that the serial number is subsequently assembled and encrypted with the corresponding hash function.
    Type: Application
    Filed: June 22, 2019
    Publication date: August 12, 2021
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Publication number: 20210245542
    Abstract: A method for producing security elements in an image which are not visible to the human eye and which cannot be copied, in particular for checking the authenticity of images. The image is imaged by means of a halftone, the halftone consisting of individual image dots arranged adjacent to each other. This is characterized in that at least one field having a random geometric shape or freeform is defined in the image/the halftone. By means of manipulation of image dots in the field and/or by means of manipulation of the entire field, an encrypted information that cannot be copied is stored for comparison with at least one database and the serial number is displayed by means of contours formed in the halftone.
    Type: Application
    Filed: June 22, 2019
    Publication date: August 12, 2021
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Publication number: 20210062198
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 4, 2021
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 10774332
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 15, 2020
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20190390201
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 3, 2019
    Publication date: December 26, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 10329568
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10323246
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10266829
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 23, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20190038557
    Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individually
    Type: Application
    Filed: February 14, 2018
    Publication date: February 7, 2019
    Inventors: Oliver KEIL, Jörg KAUFMANN, Volker FEHRING, Ute SCHAEPER
  • Publication number: 20190024089
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20180291381
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20180223286
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 15, 2017
    Publication date: August 9, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20170296469
    Abstract: The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, preferably about 250-350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 nm.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 19, 2017
    Inventors: JORG KAUFMANN, OLIVER KEIL, ANSGAR SANTEL
  • Patent number: 9790501
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese